Ambalal Sarabhai Enterprises Ltd
Incorporated in 1977, Ambalal Sarabhai Enterprises Ltd is in the business of manufacturing Pharmaceuticals and Electronics[1]
- Market Cap ₹ 241 Cr.
- Current Price ₹ 31.5
- High / Low ₹ 68.0 / 30.0
- Stock P/E 17.1
- Book Value ₹ 6.33
- Dividend Yield 0.00 %
- ROCE 6.01 %
- ROE 6.80 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
Cons
- Stock is trading at 4.98 times its book value
- Promoter holding is low: 31.4%
- Tax rate seems low
- Company has a low return on equity of 8.72% over last 3 years.
- Earnings include an other income of Rs.22.1 Cr.
- Working capital days have increased from -538 days to 109 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
16 | 15 | 7 | 2 | 1 | 0 | 0 | 0 | 0 | 4 | 4 | 4 | 5 | |
29 | 27 | 29 | 14 | 22 | 9 | 8 | 12 | 6 | 9 | 9 | 11 | 12 | |
Operating Profit | -13 | -12 | -22 | -13 | -21 | -9 | -8 | -12 | -6 | -5 | -5 | -7 | -7 |
OPM % | -85% | -79% | -310% | -858% | -2,265% | -4,292% | -139% | -126% | -181% | -160% | |||
3 | 14 | 96 | -1 | 24 | 6 | 25 | 3 | 9 | 10 | 8 | 16 | 22 | |
Interest | 9 | 8 | 2 | 3 | 1 | 1 | 0 | 1 | 0 | 0 | 2 | 0 | 0 |
Depreciation | 2 | 3 | 15 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Profit before tax | -21 | -9 | 58 | -19 | 2 | -3 | 16 | -9 | 3 | 4 | 1 | 8 | 14 |
Tax % | 0% | 0% | 21% | 10% | 166% | 13% | 2% | -1% | 14% | 5% | -217% | -2% | |
-21 | -9 | 46 | -21 | -1 | -4 | 16 | -9 | 3 | 4 | 3 | 8 | 15 | |
EPS in Rs | -2.68 | -1.19 | 5.96 | -2.68 | -0.19 | -0.51 | 2.03 | -1.23 | 0.39 | 0.54 | 0.34 | 1.08 | 1.91 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | -12% |
5 Years: | % |
3 Years: | 214% |
TTM: | 39% |
Compounded Profit Growth | |
---|---|
10 Years: | 8% |
5 Years: | -28% |
3 Years: | -4% |
TTM: | 178% |
Stock Price CAGR | |
---|---|
10 Years: | 15% |
5 Years: | 9% |
3 Years: | 0% |
1 Year: | -51% |
Return on Equity | |
---|---|
10 Years: | -11% |
5 Years: | 6% |
3 Years: | 9% |
Last Year: | 7% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 77 | 77 | 77 | 77 | 77 | 77 | 77 | 77 | 77 | 77 | 77 | 77 |
Reserves | -64 | -73 | -28 | -46 | -48 | -52 | -36 | -46 | -43 | -39 | -36 | -28 |
27 | 30 | 30 | 22 | 11 | 11 | 11 | 11 | 10 | 11 | 10 | 8 | |
97 | 103 | 65 | 64 | 91 | 103 | 73 | 58 | 40 | 30 | 31 | 27 | |
Total Liabilities | 137 | 136 | 144 | 116 | 131 | 139 | 125 | 100 | 83 | 80 | 81 | 83 |
46 | 43 | 21 | 16 | 15 | 15 | 14 | 14 | 13 | 13 | 13 | 12 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | 56 | 56 | 83 | 76 | 56 | 56 | 56 | 27 | 26 | 26 | 25 | 25 |
34 | 37 | 40 | 24 | 60 | 68 | 54 | 60 | 44 | 41 | 43 | 45 | |
Total Assets | 137 | 136 | 144 | 116 | 131 | 139 | 125 | 100 | 83 | 80 | 81 | 83 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | -12 | -69 | -4 | -13 | -3 | -5 | -10 | -8 | 2 | -4 | -4 | |
2 | 13 | 75 | 9 | 26 | 2 | 5 | 16 | 21 | 1 | 3 | 6 | |
-4 | -1 | -3 | -8 | -12 | -0 | -0 | -0 | -16 | -4 | 0 | -2 | |
Net Cash Flow | -0 | -0 | 3 | -3 | 1 | -1 | -0 | 5 | -3 | -2 | -0 | -0 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 78 | 37 | 2 | 0 | 0 | 421 | 30 | 37 | 37 | |||
Inventory Days | 6 | 76 | 23 | 48 | 57 | 0 | 2 | 0 | 0 | |||
Days Payable | 391 | 321 | 729 | 3,974 | 13,253 | 1,612 | ||||||
Cash Conversion Cycle | -307 | -207 | -705 | -3,927 | -13,197 | 421 | -1,580 | 37 | 37 | |||
Working Capital Days | -2,073 | -2,355 | -3,036 | -16,106 | -23,785 | -30,660 | -1,038 | -687 | 109 | |||
ROCE % | -22% | -34% | -60% | -13% | -22% | -7% | 37% | -4% | 10% | 11% | 6% | 6% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
14 Aug - Newspaper Publication under Regulation 30 of SEBI (LODR). Kindly take the same on your records.
- Results - Financial Results For The Quarter Ended 30.06.2025 13 Aug
-
Board Meeting Outcome for Outcome Of The Board Meeting Held On 13.08.2025
13 Aug - Q1 FY2025 unaudited results approved; Pharma Committee formed; revenue Rs.4034L, net profit Rs.822L.
-
Board Meeting Intimation for Approval Of Financial Results For The Quarter Ended 30.06.2025
4 Aug - Board meeting on Aug 13 to approve Q1 2025 unaudited results; trading window closed Jul 1-Aug 15.
-
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
1 Aug - 47th AGM held; financials adopted; directors re-appointed; secretarial auditor appointed; all resolutions passed.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
ASE is a pharmaceutical health care companies, which through its group companies, manufactures and markets pharmaceutical, molecular diagnostics, and electronics products in India and abroad